No connection

Search Results

IMDX vs MDXH

IMDX
Insight Molecular Diagnostics Inc.
BEARISH
Price
$3.17
Market Cap
$102.0M
Sector
Healthcare
AI Confidence
95%
MDXH
MDxHealth SA
BEARISH
Price
$2.14
Market Cap
$109.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
IMDX
--
MDXH
--
Forward P/E
IMDX
-3.77
MDXH
-16.46
P/B Ratio
IMDX
-2.89
MDXH
-9.3
P/S Ratio
IMDX
25.15
MDXH
1.02
EV/EBITDA
IMDX
-3.32
MDXH
-23.71

Profitability

Gross Margin
IMDX
56.84%
MDXH
64.55%
Operating Margin
IMDX
-873.57%
MDXH
-17.81%
Profit Margin
IMDX
0.0%
MDXH
-31.07%
ROE
IMDX
--
MDXH
-2440.41%
ROA
IMDX
-62.66%
MDXH
-5.9%

Growth

Revenue Growth
IMDX
-23.4%
MDXH
19.4%
Earnings Growth
IMDX
--
MDXH
--

Financial Health

Debt/Equity
IMDX
--
MDXH
--
Current Ratio
IMDX
1.27
MDXH
1.08
Quick Ratio
IMDX
1.05
MDXH
0.89

Dividends

Dividend Yield
IMDX
--
MDXH
--
Payout Ratio
IMDX
0.0%
MDXH
0.0%

AI Verdict

IMDX BEARISH

IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.

Strengths
Positive gross margin of 56.84%
Current ratio of 1.27 provides a minimal short-term liquidity buffer
Positive analyst sentiment with a target price of $8.33
Risks
Negative shareholder equity (Price/Book -2.89)
Severe revenue contraction (-23.4% YoY and Q/Q)
Extreme operating losses (-873.57% operating margin)
MDXH BEARISH

MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.

Strengths
Strong Gross Margin of 64.55%
Consistent YoY and Q/Q Revenue Growth (~19%)
Significant gap between current price and analyst target price ($7.40)
Risks
Negative Shareholder Equity (P/B of -9.30)
Extreme operational inefficiency (ROE of -2440.41%)
Chronic earnings misses with an average surprise of -31.46%

Compare Another Pair

IMDX vs MDXH: Head-to-Head Comparison

This page compares Insight Molecular Diagnostics Inc. (IMDX) and MDxHealth SA (MDXH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile